PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Conditions

• HER2-positive Breast Cancer

Interventions

• DRUG: Trastuzumab deruxtecan
• DRUG: Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
• DRUG: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection

Sponsor

MedSIR

Collaborators

• [object Object]